STD Channel
Topics & Medications
Related Channels


A healthcare provider may prescribe emtricitabine/rilpivirine/tenofovir as a complete regimen for treating HIV and AIDS. This combination medicine helps to stop the spread of HIV to uninfected cells in the body. It comes in the form of a tablet that is taken once daily with a meal. While most people tolerate this medication well, side effects may occur and can include headaches, insomnia, and increased cholesterol.

What Is Emtricitabine/Rilpivirine/Tenofovir?

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Complera™) is a prescription medicine used as a treatment for HIV and AIDS. It is an oral medication that is taken just once a day. Emtricitabine/rilpivirine/tenofovir contains three different HIV medications and can be used as a "complete" regimen for HIV treatment.
(Click What Is Emtricitabine/Rilpivirine/Tenofovir Used For? for more information, including possible off-label uses.)

Are There Side Effects?

Just like any medicine, emtricitabine/rilpivirine/tenofovir may cause side effects. However, not everyone who takes the drug will experience problems. In fact, most people tolerate it quite well.
If reactions do occur, in most cases, they are minor and either require no treatment or are treated easily by you or your healthcare provider. Serious side effects are less common.
Common side effects of emtricitabine/rilpivirine/tenofovir include but are not limited to:
(Click Emtricitabine/Rilpivirine/Tenofovir Side Effects to learn more, including potentially serious side effects you should report immediately to your healthcare provider.)

Emtricitabine/Rilpivirine/Tenofovir Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2020 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.